絞り込み

16546

広告

「elotuzumab」の検索結果

216件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

Clinical and biological characteristics of myeloma patients influence response to elotuzumab combination therapy.

Second elotuzumab triplet efficacious in MM.

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.

Elotuzumab in multiple myeloma.

Clinical impact of serum soluble SLAMF7 in multiple myeloma.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Hematologic Malignancies: Plasma Cell Disorders.

2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer.

Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.

Therapeutic antibodies for multiple myeloma.

[Immunopathogenesis and appropriate use of monoclonal antibody agents in multiple myeloma].

Response to therapeutic monoclonal antibodies for multiple myeloma in African Americans versus whites.

Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.

Practical Considerations for Antibodies in Myeloma.

Elotuzumab Plus Lenalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Extended 4-Year Follow-Up and Analysis of Relative Progression-Free Survival From the Randomized ELOQUENT-2 Trial.

Impact of elotuzumab treatment on pain and health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the ELOQUENT-2 study.

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

Carfilzomib.

Pomalidomide.

The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります